HPV16表达肿瘤释放多种IL1配体 Orchestrating 系统性免疫抑制,其阻断使治疗性疫苗有效
研究表明HPV16驱动的宫颈和皮肤鳞状细胞肿瘤向循环系统释放IL-1α、IL-1β、IL-33和IL-36β四种免疫调节配体,使骨髓偏向粒细胞性髓系生成,产生免疫抑制性中性粒细胞并聚集于脾和肿瘤。IL-1家族共受体拮抗剂抗IL1RAP可消除中性粒细胞扩增,并联合原本无效的HPV16 E7肽疫苗引发有效抗肿瘤免疫应答,抗CTLA-4可进一步维持该应答。人宫颈肿瘤中存在类似IL-1驱动的系统性免疫抑制证据,支持评估该联合治疗策略。
要点
- HPV16驱动肿瘤释放IL-1α、IL-1β、IL-33和IL-36β,诱导粒细胞性髓系生成和免疫抑制性中性粒细胞扩增。
- 抗IL1RAP阻断该中性粒细胞扩增,使原本无效的HPV16 E7肽疫苗产生有效抗肿瘤免疫应答。
- 抗CTLA-4可进一步维持抗IL1RAP联合疫苗引发的抗肿瘤免疫应答。
核心结论
- HPV16驱动肿瘤通过释放IL-1α、IL-1β、IL-33和IL-36β诱导系统性免疫抑制,阻断IL1RAP可使HPV16 E7肽疫苗有效并引发抗肿瘤免疫应答。
研究设计与样本
- 原文未报告研究设计类型与样本量。
主要发现
- HPV16驱动的宫颈和皮肤鳞状细胞肿瘤向循环系统释放IL-1α、IL-1β、IL-33和IL-36β四种免疫调节配体。
- 上述配体使骨髓偏向粒细胞性髓系生成,产生免疫抑制性中性粒细胞并聚集于脾和肿瘤。
- 抗IL1RAP消除中性粒细胞扩增,并联合原本无效的HPV16 E7肽疫苗引发有效抗肿瘤免疫应答。
- 抗CTLA-4进一步维持抗IL1RAP联合疫苗引发的抗肿瘤免疫应答。
- 人宫颈肿瘤中存在类似IL-1驱动的系统性免疫抑制证据。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: It is well-established that symptomatic cancers evade immune destruction by coalescing tumor microenvironments to suppress adaptive immunity. Additionally, mouse models of cervical and other cancers have revealed a capability of tumors to systemically induce the expansion of neutrophils that cripple T-cell development in spleen and lymph nodes, further impairing immune responses. Now we show that human papillomavirus type 16 (HPV16)-driven squamous cell tumors in the cervix and skin release into the circulatory system four immunoregulatory ligands - IL-1α, IL-1β, IL-33, and IL-36β - that bias the bone marrow toward granulocytic myelopoiesis, producing immunosuppressive neutrophils populating spleens and tumors. An IL-1 family coreceptor antagonist, anti-IL1RAP, abrogates this neutrophil expansion and complements an otherwise inefficacious HPV16 E7 peptide vaccine to elicit an effective antitumor immune response that is further sustained by anti-CTLA-4. Evidence for similarly IL-1-driven systemic immunosuppression in human cervical tumors encourages evaluation of this combinatorial therapeutic strategy for treating a largely immunoevasive cancer type. SIGNIFICANCE: Cervical cancer is the fourth leading cause of cancer deaths in women worldwide. Although the disease is driven by two antigenic viral oncoproteins, therapeutic vaccines have proved ineffective, inferentially due to systemic immunosuppression. This study elucidated an actionable mechanism, whose disruption renders an oncoprotein vaccine efficacious, with translational potential.
引用
- Lecointre M, Guillot J, Marcone R, et al. HPV16-Expressing Tumors Release Multiple IL1 Ligands to Orchestrate Systemic Immunosuppression Whose Disruption Enables Efficacy of a Therapeutic Vaccine. Cancer Discov. 2025. PMID: 40287949. doi:10.1158/2159-8290.CD-25-0382
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。